Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 268-279

  Niknejad, Nima ^a,b   Gorn Hondermann, Ivan ^a   Ma, Laurie ^a   Zahr, Stephanie ^a,b   Johnson Obeseki, Stephanie ^c   Corsten, Martin ^c   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

activating transcription factor 3; integrated stress response; lovastatin; salubrinal

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CASPASE 3; MESSENGER RNA; MEVINOLIN; SALUBRINAL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR 3;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA;

ACTIVATING TRANSCRIPTION FACTOR 3; INTEGRATED STRESS RESPONSE; LOVASTATIN; SALUBRINAL;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CINNAMATES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EMBRYO, MAMMALIAN; EUKARYOTIC INITIATION FACTOR-2; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOENZYME TECHNIQUES; LOVASTATIN; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; THIOUREA; TUMOR CELLS, CULTURED;

EID: 84887419206     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28369     Document Type: Article

References (47)

1. Buchwald H,. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992; 339: 1154-6.
2. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-19. (Pubitemid 34460459)
3. Corsini A, Maggi FM, Catapano AL,. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
4. Dimitroulakos J, Yeger H,. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996; 2: 326-33. (Pubitemid 26082012)
5. Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-9.
6. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-17. (Pubitemid 34116983)
7. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
8. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999; 93: 1308-18. (Pubitemid 29076146)
9. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001; 7: 158-67. (Pubitemid 32110219)
10. Knox JJ, Siu LL, Chen E, et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41: 523-30. (Pubitemid 40292732)
11. Niknejad N, Morley M, Dimitroulakos J,. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 2007; 282: 29748-56. (Pubitemid 350035248)
12. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619-33. (Pubitemid 36385118)
13. Rutkowski DT, Kaufman RJ,. All roads lead to ATF4. Dev Cell 2003; 4: 442-4. (Pubitemid 36437550)
14. Wek RC, Jiang HY, Anthony TG,. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006; 34: 7-11. (Pubitemid 43235522)
15. Vattem KM, Wek RC,. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA 2004; 101: 11269-74. (Pubitemid 39038336)
16. Holcik M, Sonenberg N,. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005; 6: 318-27. (Pubitemid 40516898)
17. Hai T, Hartman MG,. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 2001; 273: 1-11. (Pubitemid 32718721)
18. Hai T, Wolfgang CD, Marsee DK, et al. ATF3 and stress responses. Gene Expr 1999; 7: 321-35. (Pubitemid 29372076)
19. Blais JD, Filipenko V, Bi M, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004; 24: 7469-82. (Pubitemid 39121475)
20. Jiang HY, Wek RC,. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 2005; 280: 14189-202. (Pubitemid 40517321)
21. St Germain C, Niknejad N, Ma L, et al. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. Neoplasia 2010; 12: 527-38.
22. Turchi L, Aberdam E, Mazure N, et al. Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ 2008; 15: 1472-80.
23. Mantha AJ, Hanson JE, Goss G, et al. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005; 11: 2398-407. (Pubitemid 40490201)
24. Smiley ST, Reers M, Mottola-Hartshorn C, etal. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991; 88: 3671-5. (Pubitemid 21916685)
25. Imai A, Zeitlin BD, Visioli F, et al. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res 2012; 72: 716-25.
26. Zhao TT, Le Francois BG, Goss G, et al. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 2010; 29: 4682-92.
27. Ma L, Niknejad N, Gorn-Hondermann I, et al. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PLoS One 2012; 7: e46055.
28. Dimitroulakos J, Marhin WH, Tokunaga J, et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002; 4: 337-46. (Pubitemid 34755844)
29. Jiang CC, Lucas K, Avery-Kiejda KA, et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 2008; 68: 6708-17.
30. Krysko DV, Vanden Berghe T, D'Herde K, et al. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 2008; 44: 205-21. (Pubitemid 351296447)
31. 2+ channels in endoplasmic reticulum stress and beta-cell death. Diabetes 2009; 58: 422-32.
32. Duriez PJ, Shah GM,. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997; 75: 337-49. (Pubitemid 127733184)
33. Lu D, Chen J, Hai T,. The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J 2007; 401: 559-67. (Pubitemid 46166437)
34. Lu D, Wolfgang CD, Hai T,. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 2006; 281: 10473-81. (Pubitemid 43864586)
35. Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-9. (Pubitemid 40229232)
36. Bottone FG, Jr, Moon Y, Alston-Mills B, et al. Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene. J Pharmacol Exp Ther 2005; 315: 668-77. (Pubitemid 41500732)
37. Cai Y, Zhang C, Nawa T, et al. Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood 2000; 96: 2140-8.
38. Fawcett TW, Martindale JL, Guyton KZ, et al. Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem J 1999; 339 (Part 1): 135-41. (Pubitemid 29179300)
39. Jiang HY, Wek SA, McGrath BC, et al. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 2004; 24: 1365-77. (Pubitemid 38112196)
40. Wolfgang CD, Chen BP, Martindale JL, et al. gadd153/Chop10, a potential target gene of the transcriptional repressor ATF3. Mol Cell Biol 1997; 17: 6700-7. (Pubitemid 27451217)
41. Drexler HC,. Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One 2009; 4: e4161.
42. Schewe DM, Aguirre-Ghiso JA,. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 2009; 69: 1545-52.
43. O'Brien A, Barber JE, Reid S, et al. Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3. Anticancer Res 2012; 32: 2679-88.
44. St Germain C, O'Brien A, Dimitroulakos J,. Activating transcription factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. Cancer Cell Int 2010; 10: 32.
45. Goldstein JL, Brown MS,. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
46. Sebti S, Hamilton AD,. Inhibitors of prenyl transferases. Curr Opin Oncol 1997; 9: 557-61. (Pubitemid 27480859)
47. Novoa I, Zeng H, Harding HP, et al. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 2001; 153: 1011-22.